MTOR and hepatocellular carcinoma: Therefore, we further explored the correlation between the PI3K/AKT/mTOR pathway-associated prognostic signature (PAPS) and the related ratio of infiltrating immune cells in TME, aimed at monitoring the individualized immunotherapy and predicting the prognosis for HCC patients.